NCT00038246 - Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

February 29, 2004

Study Completion Date

December 31, 2004

Conditions

Prostate Cancer

Interventions

DRUG

Estramustine

140 mg by mouth (po) three times a day on Days 1-5, 8-12

DRUG

Thalidomide

200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.

DRUG

Paclitaxel (Taxol)

100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10

Trial Locations (1)

UT MD Anderson Cancer Center, Houston